



18W

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re United States Patent Application of:

Docket No.: 4121-180

Applicants: **ARENDT, Thomas, et al.**

Conf. No.: 5650

Application No.: 10/576,142

Art Unit:

Date Filed: April 18, 2006

Examiner: Not Yet Assigned

Title: QUICK TEST FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE

Customer No.:

23448

FIRST CLASS MAIL CERTIFICATE

I hereby certify that I am mailing the attached documents to the Commissioner for Patents on the date specified, in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313, First Class Mailed under the provisions of 37 CFR 1.8.

Barbara Owens

December 11, 2006

Date of Mailing

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN
U.S. PATENT APPLICATION NO. 10/576,142**

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450**

Sir:

Pursuant to 37 C.F.R. §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO/SB/08A. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of

this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

- ☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).
- ☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- ☒ c. Attached is credit card form in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Please credit or debit Deposit Account No. 08-3284 as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

Respectfully submitted,



Steven J. Hultquist
Reg. No. 28,021
Attorney for Applicants

INTELLECTUAL PROPERTY/
TECHNOLOGY LAW
Phone: (919) 419-9350
Fax: (919) 419-9354
Attorney File No.: 4121-180

Enclosures:
IDS Forms [3 pg(s).]
Non-Patent References [145 pgs.]
Confirmation Postcard [1 pg.]
Credit Card Form [1 pg.]

<p>The USPTO is hereby authorized to charge any deficiency or credit any overpayment of fees properly payable for this document to Deposit Account No. 08-3284</p>
--



PTO/SB/08A (01-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION
DISCLOSURE STATEMENT
BY APPLICANT**

Sheet 1 of 3

COMPLETE IF KNOWN

Application Number	10/576,142
Filing Date	April 18, 2006
First Named Inventor	ARENDT, et al.
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	4121-180

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AA	US-2002/0081635 A1	June 27, 2002		Thomas et al.
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Examiner signature		Date Considered	
-----------------------	--	--------------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

¹ All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">Sheet 2 of 3</p>	<i>COMPLETE IF KNOWN</i>	
	Application Number	10/576,142
	Filing Date	April 18, 2006
	First Named Inventor	ARENDT, et al.
	Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	4121-180

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AB	ARENDT, T., ET AL., Aberrancies in signal transduction and cell cycle related events in Alzheimer's disease, Journal of Neural Transmission, 1998, Page(s) 147-158, Supplement 54, Springer-Verlag Wien, New York	
	AC	ARENDT, THOMAS, ET AL., Activated Mitogenic Signaling Induces a Process of Dedifferentiation in Alzheimer's Disease That Eventually Results in Cell Death, Annals New York Academy of Sciences, Page(s) 249-255	
	AD	ARENDT, THOMAS, Alzheimer's disease as a loss of differntiation control in a subject of neurons that retain immature features in the adult brain, Neurobiology of Aging, 2000, Page(s) 783-796, Elsevier Science Inc.	
	AE	ARENDT, T., ET AL., Increased Expression and Subcellular Translocation of the Mitogen Activated Protein Kinase Kinase and Mitogen-Activated Protein Kinase in Alzheimer's Disease, Neuroscience, 1995, Page(s) 5-18, Volume 68, Number 1, Elsevier Science Ltd., Great Britain	
	AF	ARENDT, THOMAS, ET AL., Neuronal activation of Ras regulations synaptic connectivity, European Jounal of Neuroscience, 2004, Page(s) 2953-2966, Volume 19, Federation of European Neuroscience Socities	
	AG	ARENDT, T., ET AL., Neuronol expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease, Journal of Neural Transmission, 1998, Page(s) 949-960, Volume 105, Springer-Verlag, Austria	
	AH	GÄRTNER, M., ET AL., Letter to Neuroscience Elevated Expression of p21 ^{ras} is an Early Event in Alzheimer's Disease and Precedes Neurofibrillary Degeneration, Neuroscience, 1999, Page(s) 1-5, Volume 91, Number 1, Elsevier Science Ltd., Great Britain	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).

<p align="center">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p align="center">Sheet 3 of 3</p>	<i>COMPLETE IF KNOWN</i>	
	Application Number	10/576,142
	Filing Date	April 18, 2006
	First Named Inventor	ARENDT, et al.
	Art Unit	Unassigned
	Examiner Name	Unassigned
	Attorney Docket Number	4121-180

NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AI	HOLZER, M., ET AL., Activation of Mitogen-Activated Protein Kinase Cascade and Phosphorylation of Cytoskeletal Proteins After Neurone-Specific Activation of P21RAS. I. Mitogen-Activated Protein Kinase Cascade, Neuroscience, 2001, Page(s) 1031-1040, Volume 105, Number 4, Elsevier Science Ltd., Great Britain	
	AJ	HOLZER, M., ET AL., Activation of Mitogen-Activated Protein Kinase Cascade and Phosphorylation of Cytoskeletal Proteins After Neurone-Specific Activation of P21RAS. II. Cytoskeletal Proteins and Dendritic Morphology, Neuroscience, 2001, Page(s) 1041-1054, Volume 105, Number 4, Elsevier Science Ltd., Great Britain	
	AK	SCHMETSDORF, STEFANIE, ET AL., Expression of cell cycle-related proteins in developing and adult mouse hippocampus, International Journal of Developmental Neuroscience, 2005, Page(s) 101-112, Volume 23, Elsevier Ltd.	
	AL	UEBERHAM, U., ET AL., Letter to Neuroscience Connective Tissue Growth Factor in Alzheimer's Disease, Neuroscience, 2003, Page(s) 1-6, Volume 116, Elsevier Science Ltd on behalf of IBRO	
	AM	UEBERHAM, UWE, ET AL., Cyclin C expression is involved in the pathogenesis of Alzheimer's disease, Neurobiology of Aging, 2003, Page(s) 427-435, Volume 24, Elsevier Science Inc.	
	AN	UEBERHAM, UWE, ET AL., The Expression of Cell Cycle Proteins in Neurons and its Relevance for Alzheimer's Disease, Current Drug Targets – CNS & Neurological Disorders, 2005, Page(s) 293-306, Volume 4, Bentham Science Publishers Ltd.	

Examiner signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

² Applicant is to place a check mark here if English Translation is attached. All the foreign patents and publications that are not written in English language are accompanied by their respective English abstracts, which constitute concise explanation of relevance of the non-English patents and publications that satisfy the requirements of 37 C.F.R. §1.98(a)(3)(i), according to MPEP 609 III A(3).